The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- FCT actors guild begins membership cleanup
- Lagos urges Heightened vigilance against lassa fever
- NAFDAC clears BON bread of mould controversy
- Association warns against consuming fungus-infested tomatoes
- NDLEA intercepts UK, Australia-bound drugs, destroys 65,000kg skunk
- Nigeria to gain big from China zero-tariff policy
- Association backs new ports economic regulator
- Expert urges women to prioritise regular health screenings
